Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis

2007 ◽  
Vol 28 (4) ◽  
pp. 175-180 ◽  
Author(s):  
Z. R. Gao ◽  
C. Kornblum ◽  
S. Flacke ◽  
T. Logvinski ◽  
M. Yüksel ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

scholarly journals Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix

2020 ◽  
Vol 8 (17) ◽  
pp. 3697-3707
Author(s):  
Jelena Saponjski ◽  
Djuro Macut ◽  
Dragana Sobic-Saranovic ◽  
Sanja Ognjanovic ◽  
Ivana Bozic Antic ◽  
...  
Keyword(s):  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Neuroendocrine Neoplasms ◽  
Receptor Scintigraphy

Bone Lesion in a Patient with Transplanted Liver for a Metastatic Carcinoid. The Role of Somatostatin Receptor Scintigraphy

1998 ◽  
Vol 84 (1) ◽  
pp. 82-84 ◽  
Author(s):  
Giordano Savelli ◽  
Arturo Chiti ◽  
Antonella Spinelli ◽  
Enrico Regalia ◽  
Vincenzo Mazzaferro ◽  
...  
Keyword(s):  
Imaging Techniques ◽  
Somatostatin Receptor ◽  
Bone Lesion ◽  
Somatostatin Receptor Scintigraphy ◽  
Resonance Imaging ◽  
Metastatic Carcinoid ◽  
Ultrasound Computed Tomography ◽  
Receptor Scintigraphy

A patient who had previously undergone ileal resection and liver transplantation for a gastroenteropancreatic (GEP) tumor was evaluated with somatostatin receptor scintigraphy (SRS) using 111In-DTPA-D-Phe1-pentetreotide. Eighteen months after surgery, during follow-up procedures, conventional imaging techniques (ultrasound, computed tomography, magnetic resonance imaging) only showed a relapse in the gastropancre-atic lymph nodes, while SRS demonstrated skeletal spread. This case report emphasizes the clinical impact of SRS on the management of patients affected by neuroendocrine gastroenteropancreatic tumors.

scholarly journals Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

2006 ◽  
Vol 13 (4) ◽  
pp. 1203-1211 ◽  
Author(s):  
Martin Gotthardt ◽  
Martin P Béhé ◽  
Julia Grass ◽  
Artur Bauhofer ◽  
Anja Rinke ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Added Value ◽  
Imaging Method ◽  
Gastrin Receptor ◽  
Additional Information ◽  
Receptor Scintigraphy ◽  
Better Than

Gastrin receptor scintigraphy (GRS) is a new imaging method primarily developed for the detection of metastases of medullary thyroid carcinoma (MTC). As gastrin-binding CCK2 receptors are also expressed on a variety of other neuroendocrine tumours (NET), we compared GRS to somatostatin receptor scintigraphy (SRS) in patients with NET. SRS and GRS were performed within 21 days in a series of 60 consecutive patients with NET. GRS was directly compared with SRS. If lesions were visible on GRS but not detectable by SRS, other imaging modalities (MRI, CT) and follow-up were used for verification. Of the 60 evaluable patients, 51 had carcinoid tumours, 3 gastrinomas, 2 glucagonomas, 1 insulinoma and 3 paragangliomas. The overall tumour-detection rate was 73.7% for GRS and 82.1% for SRS. In the 11 patients with negative SRS, GRS was positive in 6 (54.5%). Based on the number of tumour sites detected and the degree of uptake, GRS performed better than SRS in 13 patients (21.7%), equivalent images were obtained in 18 cases (30.0%) and SRS performed better in 24 (40.0%) cases. In six of the SRS positive patients, 18 additional sites of tumour involvement could be detected. Overall, GRS detected additional tumour sites in 20% of the patients. Localisation of the primary tumours or their functional status had no influence on the outcome of imaging. GRS should be performed in selected patients as it may provide additional information in patients with NET with equivocal or absent somatostatin uptake.

Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer

2001 ◽  
Vol 24 (6) ◽  
pp. 415-422 ◽  
Author(s):  
L. M. Haslinghuis ◽  
E. P. Krenning ◽  
W. W. de Herder ◽  
A. E. M. Reijs ◽  
D. J. Kwekkeboom
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

scholarly journals The role of somatostatin receptor scintigraphy in the diagnosis and follow-up of the pancreatic neuroendocrine neoplasms

2020 ◽  
Vol 35 (3) ◽  
pp. 261-267
Author(s):  
Jelena Saponjski ◽  
Dragana Sobic-Saranovic ◽  
Djuro Macut ◽  
Tatjana Isailovic ◽  
Nikola Bogosavljevic ◽  
...  
Keyword(s):  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Neuroendocrine Neoplasms ◽  
True Positive ◽  
True Negative ◽  
Primary Tumors ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Receptor Scintigraphy

The aim of investigation was to assess the role of somatostatin receptor scintigraphy in diagnosis and follow-up of pancreatic neuroendocrine neoplasms. Somatostatin receptor scintigraphy was performed with 740 MBq 99mTc-EDDA/HYNIC TOC for diagnosis of primary tumors and follow-up after the therapy. There were 63 true positive, 24 true negative, 4 false positive, and 6 false negative findings. Sensitivity was 91.3 %, specificity 85.7 %, positive predictive value 94.0 %, negative predictive value 80.0 %, accuracy 89.7 %. The SPECT contributed diagnosis in 28 true positive findings. In 32 patients (33 %) somatostatin receptor scintigraphy significantly changed the management of the patients (10 had surgery, in 17 somatostatin analogues, and in 5 peptide receptor radionuclide therapy was introduced). Mean Ki-67 index in true positive patients was 13.8 ?5.0 % while in true negative 7.1 ? 3.4% which is significantly lower at p < 0.05. There was significantly (p < 0.01) higher number of increased chromogranin A values in true positive than in true negative patients (p = 0.000857). Our results confirmed the value of SRS in the diagnosis and follow-up of the patients with pancreatic neuroendocrine neoplasms PanNEN if primary tumors, recurrences or metastases are suspected, as well as for appropriate choice of the therapy.

Somatostatin Receptor Scintigraphy for Bronchial Carcinoid Follow-Up

2003 ◽  
Vol 28 (7) ◽  
pp. 548-552 ◽  
Author(s):  
STEFANO FANTI ◽  
MOHSEN FARSAD ◽  
GIUSEPPE BATTISTA ◽  
FRANCESCO MONETTI ◽  
GIAN CARLO MONTINI ◽  
...  
Keyword(s):  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Bronchial Carcinoid ◽  
Receptor Scintigraphy
Sign in / Sign up

Export Citation Format

Share Document